Ruxolitinib cream is a topical medication indicated for the treatment of nonsegmental vitiligo in patients 12 years of age and older [1]. It is a Janus kinase (JAK) inhibitor, specifically targeting JAK1 and JAK2 [2].
How does Ruxolitinib cream work for vitiligo?
Ruxolitinib cream works by inhibiting the activity of JAK enzymes. These enzymes are involved in signaling pathways that regulate immune responses and inflammation. In vitiligo, a component of the immune system attacks melanocytes, the cells responsible for skin pigmentation. By inhibiting JAK signaling, ruxolitinib cream is thought to reduce this immune-mediated destruction of melanocytes, thereby allowing for repigmentation [2].
When might Ruxolitinib cream become available for patients?
Ruxolitinib cream was approved by the U.S. Food and Drug Administration (FDA) in July 2023 for the treatment of nonsegmental vitiligo [1].
What is the difference between Ruxolitinib cream and oral Ruxolitinib?
Ruxolitinib is also available as an oral medication, primarily used to treat myelofibrosis and polycythemia vera. The cream formulation is specifically designed for topical application to the skin for vitiligo, whereas the oral form is systemic [2].
What are the potential side effects of Ruxolitinib cream?
Common side effects of Ruxolitinib cream can include acne, rash, itching, redness, pain, and changes in hair color at the application site [1].
How effective is Ruxolitinib cream in clinical trials?
Clinical trials demonstrated that Ruxolitinib cream led to significant facial and non-facial repigmentation in patients with nonsegmental vitiligo. For example, in one study, over 50% of patients treated with the cream achieved at least a 50% improvement in facial skin color from baseline at week 24 [1].
Are there any patent expirations for Ruxolitinib cream?
Information on specific patent expiry dates for Ruxolitinib cream can be found on resources like DrugPatentWatch.com [3].
What are other treatment options for vitiligo?
Besides Ruxolitinib cream, other treatments for vitiligo include topical corticosteroids, topical calcineurin inhibitors, phototherapy (like narrowband UVB), and surgical procedures like skin grafting [4].
Who makes Ruxolitinib cream?
Ruxolitinib cream is manufactured by Incyte Corporation [1].
---
Sources:
[1] https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-opzelura-ruxolitinib-cream-treatment-nonsegmental-vitiligo
[2] https://www.drugpatentwatch.com/ruxolitinib
[3] https://www.drugpatentwatch.com/ruxolitinib
[4] https://www.mayoclinic.org/diseases-conditions/vitiligo/diagnosis-treatment/drc-20353949